血栓调节蛋白
凝血酶
化学
血小板
血小板缺乏血浆
凝血酶原酶
肝素
内科学
凝血因子
血管性血友病因子
内分泌学
药理学
生物化学
医学
作者
H.C. Hemker,Peter Giesen,Raed Al Dieri,Véronique Regnault,E. DE SMEDT,Rob Wagenvoord,Thomas Lecompte,Suzette Beguı́n
出处
期刊:Pathophysiology of Haemostasis and Thrombosis
[Karger Publishers]
日期:2003-01-01
卷期号:33 (1): 4-15
被引量:1354
摘要
Calibrated automated thrombography displays the concentration of thrombin in clotting plasma with or without platelets (platelet-rich plasma/platelet-poor plasma, PRP/PPP) in up to 48 samples by monitoring the splitting of a fluorogenic substrate and comparing it to a constant known thrombin activity in a parallel, non-clotting sample. Thus, the non-linearity of the reaction rate with thrombin concentration is compensated for, and adding an excess of substrate can be avoided. Standard conditions were established at which acceptable experimental variation accompanies sensitivity to pathological changes. The coefficients of variation of the surface under the curve (endogenous thrombin potential) are: within experiment ∼3%; intra-individual: <5% in PPP, <8% in PRP; interindividual 15% in PPP and 19% in PRP. In PPP, calibrated automated thrombography shows all clotting factor deficiencies (except factor XIII) and the effect of all anticoagulants [AVK, heparin(-likes), direct inhibitors]. In PRP, it is diminished in von Willebrand’s disease, but it also shows the effect of platelet inhibitors (e.g. aspirin and abciximab). Addition of activated protein C (APC) or thrombomodulin inhibits thrombin generation and reflects disorders of the APC system (congenital and acquired resistance, deficiencies and lupus antibodies) independent of concomitant inhibition of the procoagulant pathway as for example by anticoagulants.
科研通智能强力驱动
Strongly Powered by AbleSci AI